Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

125.26 -0.59 (-0.47%)
Official Closing Price Updated: 7:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,467,082
Open 127.24
Bid (Size) 123.80 (1)
Ask (Size) 125.50 (5)
Prev. Close 125.85
Today's Range 125.05 - 128.73
52wk Range 99.14 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.33%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Merck & Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
From Merck & Co., Inc.
Via Business Wire

Performance

YTD
+10.61%
+10.61%
1 Month
-5.76%
-5.76%
3 Month
-4.18%
-4.18%
6 Month
+4.27%
+4.27%
1 Year
+16.91%
+16.91%

More News

Read More
Smart Money Is Betting Big In MRK Options
Via Benzinga
Earnings Divide Dow Industrials As Crux Of Q2 Season Approaches
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
Via Benzinga
Merck & Co Inc. DCF Valuation: Is The Stock Undervalued?
Via Talk Markets
Merck & Co's Options Frenzy: What You Need to Know
Via Benzinga
Merck Announces Fourth-Quarter 2024 Dividend
From Merck & Co., Inc.
Via Business Wire
Billionaires Are Loading Up on This Surging Dow Stock. Should You?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants
From Merck & Co., Inc.
Via Business Wire
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
Via The Motley Fool
Evaluating Merck & Co Against Peers In Pharmaceuticals Industry
Via Benzinga
NYSE:MRK is probably undervalued for the fundamentals it is displaying.
Via Chartmill
Merck's Acquisition of EyeBio Finalized
Via Benzinga
This Hidden Gem Vanguard ETF Is Chock-Full of Magnificent Stocks. Here's Why It's a Buy Now.
Via The Motley Fool
Topics ETFs
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
Via Investor's Business Daily
Merck Gets Legal Victory As Appeals Court Dismisses Shingles Vaccine Some 1,200 Lawsuits
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
2 Magnificent Stocks to Buy With $500
Via The Motley Fool
3 Top Cancer Treatment Stocks to Buy Now
Via InvestorPlace
3 Biotech Stocks to Buy in Case of Another Pandemic
Via InvestorPlace
Merck to Share New Research and Host Community-Focused Symposia at AIDS 2024
From Merck & Co., Inc.
Via Business Wire
Forget Nvidia: Billionaires Are Dumping It and Piling Into These 3 Surprising Value Stocks Instead
Via The Motley Fool
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Positive News is Driving This Cancer Drug Maker’s Stock Higher
Via MarketBeat
Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.